

Supplementary Table 1. Distribution of incidence and prevalence rate of intravitreal ranibizumab and aflibercept injection

Year	Total			Ranibizumab			Aflibercept			Total			Ranibizumab			Aflibercept		
	New patients on treatment/total new patients	Injections in each study year	Mean number of injections	New patients on treatment/total new patients	Injections in each study year	Mean number of injections	New patients on treatment/total new patients	Injections in each study year	Mean number of injections	Prevalent patients	Injections in each study year	Injections per prevalent patients	Prevalent patients	Injections in each study year	Injections per prevalent patients	Prevalent patients	Injections in each study year	Injections per prevalent patients
2010	4,146/6,591 (62.9)	11,980	2.89 (1-10)	4,146/6,591 (62.9)	11,980	2.89 (1-10)	1,908/7,124 (26.8)	4,786	2.51 (1-7)	18,199/89,979 (20.2)	1.15	7,662/89,979 (8.5)	20,956	2.74	7,662/89,979 (8.5)	20,956	2.74	
2011	4,308/6,299 (68.4)	12,487	2.90 (1-11)	4,308/6,299 (68.4)	12,487	2.90 (1-11)	3,256/10,029 (32.5)	9,257	2.84 (1-11)	20,403/94,054 (21.7)	0.96	7,424/94,054 (7.9)	19,579	2.64	7,424/94,054 (7.9)	19,579	2.64	
2012	4,169/6,202 (67.2)	12,141	2.91 (1-10)	4,169/6,202 (67.2)	12,141	2.91 (1-10)	4,224/11,064 (38.2)	12,030	2.85 (1-10)	23,373/97,818 (23.9)	0.81	7,200/97,818 (7.4)	18,821	2.61	7,200/97,818 (7.4)	18,821	2.61	
2013	4,472/6,600 (67.8)	13,183	2.95 (1-10)	4,472/6,600 (67.8)	13,183	2.95 (1-10)	5,202/11,866 (43.8)	15,260	2.93 (1-12)	26,494/101,599 (26.1)	1.03	9,444/101,599 (9.3)	27,364	2.90	9,444/101,599 (9.3)	27,364	2.90	
2014	4,881/7,124 (68.5)	14,259	2.92 (1-10)	3,103/7,124 (43.6)	9,473	3.05 (1-10)	3,256/10,029 (32.5)	9,257	2.84 (1-11)	30,340/105,739 (28.7)	0.99	8,505/105,739 (8.0)	23,684	2.78	8,505/105,739 (8.0)	23,684	2.78	
2015	6,470/10,029 (64.5)	20,041	3.13 (1-13)	3,602/10,029 (35.9)	5,923	2.99 (1-13)	4,224/11,064 (38.2)	12,030	2.85 (1-10)	35,169/112,523 (31.3)	1.38	9,171/112,523 (8.2)	25,810	2.81	9,171/112,523 (8.2)	25,810	2.81	
2016	6,968/11,064 (63.0)	21,572	3.10 (1-11)	3,146/11,064 (28.4)	6,542	3.03 (1-10)	2,692/11,866 (22.7)	7,081	2.97 (1-13)	41,839/120,088 (34.8)	1.24	8,249/120,088 (6.9)	22,744	2.76	8,249/120,088 (6.9)	22,744	2.76	
2017	7,560/11,866 (63.7)	23,263	3.08 (1-13)	3,050/12,896 (23.7)	7,616	2.86 (1-12)	5,554/12,896 (43.1)	15,722	2.83 (1-13)	48,534/128,128 (37.9)	1.22	7,363/128,128 (5.7)	20,002	2.72	7,363/128,128 (5.7)	20,002	2.72	
2018	8,229/12,896 (63.8)	24,440	2.97 (1-13)	2,909/11,340 (25.7)	6,566	2.98 (1-16)	4,702/11,340 (41.5)	13,499	2.87 (1-13)	55,990/136,924 (40.9)	1.33	8,252/136,924 (6.0)	23,490	2.85	8,252/136,924 (6.0)	23,490	2.85	
2019	7,268/11,340 (64.1)	22,154	3.05 (1-16)	3,597/90,011 (39.5)	104,966	2.95 (1-16)	24,846/90,011 (27.6)	70,554	2.84 (1-13)	61,623/143,501 (42.9)	1.44	8,906/143,501 (6.2)	27,794	3.12	8,906/143,501 (6.2)	27,794	3.12	
Total	58,471/90,011 (65.0)	175,520	3.00 (1-16)	36,196/115,034 (32.0)	43,982	1.22	8,218/113,034 (7.3)	23,024	2.8	36,196/115,034 (32.0)	1.22	8,218/113,034 (7.3)	23,024	2.8	36,196/115,034 (32.0)	23,024	2.8	
Mean																		

Values are presented as number (% on range).